GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Prelude Therapeutics
Prelude is a biotech company developing targeted cancer therapies. Its stock price is driven by news from its clinical trials. The chart reflects investor confidence in the potential of its scientific platform for developing new drugs.
Share prices of companies in the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule drugs that target key signaling pathways in cancer cells. We've classified it in the "Cancer Lymphocytes" segment. The chart below shows the overall dynamics of the targeted cancer therapy sector.
Broad Market Index - GURU.Markets
Prelude Therapeutics is an oncology company developing targeted therapies for the treatment of cancer, particularly lymphoma and solid tumors. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PRLD - Daily change in the company's share price Prelude Therapeutics
Prelude Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its cancer drugs.
Daily change in the price of a set of shares in a market segment - Cancer lymphonodes
Prelude Therapeutics Incorporated is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with PRLD's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Prelude Therapeutics is a biotech company focused on developing targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Prelude Therapeutics
For Prelude Therapeutics, year-over-year performance is a reflection of its extensive early-stage oncology pipeline. Its 12-month market cap is entirely dependent on clinical trial data. The success of any of its candidates targeting key signaling pathways in cancer cells could fundamentally change its valuation.
Annual dynamics of market capitalization of the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biotech company developing targeted therapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Prelude Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Prelude Therapeutics
Prelude Therapeutics is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its small-molecule drug portfolio triggers an immediate investor reaction, which is typical for biotech.
Monthly dynamics of market capitalization of the market segment - Cancer lymphonodes
Targeted oncology biotechnology is at the cutting edge of science, where companies strive to develop highly precise cancer treatments. The dynamics of this sector, as seen in the chart, reflect the high level of risk and investor confidence in scientific breakthroughs. Prelude Therapeutics is one company operating in this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Prelude Therapeutics is an early-stage oncology company. Its shares exist in their own news cycle, rising and falling based on research data. Their performance is completely disconnected from overall market sentiment, as the chart illustrates.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Prelude Therapeutics
Prelude Therapeutics, a clinical-stage oncology company, is experiencing extremely volatile weekly performance. Any data, even interim, from clinical trials of its targeted drugs could cause sharp and significant price movements, reflecting the high risks.
Weekly dynamics of market capitalization of the market segment - Cancer lymphonodes
Prelude Therapeutics and the entire oncology biotech sector are riding the wave of industry-wide news and sentiment. Breakthroughs in targeted therapies or changes in FDA policy could boost the entire industry. The chart below will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Prelude Therapeutics and the entire oncology biotech sector are riding the wave of industry-wide news and sentiment. Breakthroughs in targeted therapies or changes in FDA policy could boost the entire industry. The chart below will show how the company stacks up against this high-risk segment.
Market capitalization of the company, segment and market as a whole
PRLD - Market capitalization of the company Prelude Therapeutics
Prelude Therapeutics' market capitalization is the financial valuation of a biotech company focused on developing targeted drugs for early-stage cancer treatment. The chart reflects investor expectations for its scientific platform. Its speculative dynamics tell the story of how the market evaluates preclinical and early clinical data in oncology.
PRLD - Share of the company's market capitalization Prelude Therapeutics within the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for the treatment of cancer. Its market share reflects the value of its broad pipeline of developments targeting key oncogenic pathways. The chart below shows how the market values its multiple "shots on target."
Market capitalization of the market segment - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company focused on cancer treatment. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the company's massive investment in drug discovery. Like many, Prelude is betting on a few molecules in early development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Oncology, as seen on the graph, requires a constant search for new targets. Prelude Therapeutics develops small molecules that target key signaling pathways in cancer cells. Its capitalization represents a risky bet on its early-stage pipeline.
Book value capitalization of the company, segment and market as a whole
PRLD - Book value capitalization of the company Prelude Therapeutics
Prelude Therapeutics' book value is capital for the development of small-molecule cancer drugs. Currently in the R&D stage, the company uses its financial assets to advance a pipeline of candidates targeting key signaling pathways that drive tumor growth.
PRLD - Share of the company's book capitalization Prelude Therapeutics within the market segment - Cancer lymphonodes
Prelude Therapeutics, a biopharmaceutical company focused on oncology, has R&D assets. Its share in the sector reflects investments in laboratories to develop its small molecules. The company's value lies in its scientific platform and development pipeline.
Market segment balance sheet capitalization - Cancer lymphonodes
Prelude Therapeutics is an R&D-stage oncology company, making its model intellectually rather than capital-intensive. The company's value lies in its drug discovery platform. Compared to the broader biotech sector, its "light" balance sheet is typical of companies at the forefront of science.
Book value of all companies included in the broad market index - GURU.Markets
Prelude's assets comprise a scientific platform focused on discovering new drugs that target key signaling pathways within cancer cells. The company's balance sheet reflects the value of its extensive library of compounds and preclinical data. The chart shows the capital invested in this fundamental search for cancer vulnerabilities.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Prelude Therapeutics
Prelude Therapeutics is a clinical-stage oncology company. Its market capitalization is a valuation of its scientific platform for discovering new small-molecule drugs. Investors are betting on its approach to drug development, creating a huge gap with its book value.
Market to book capitalization ratio in a market segment - Cancer lymphonodes
Prelude Therapeutics is a biotech company focused on cancer treatments. Its market capitalization is based on the potential of its early-stage R&D pipeline. This chart clearly demonstrates how investor expectations for its R&D platform shape a valuation that is disconnected from the reality of its balance sheet.
Market to book capitalization ratio for the market as a whole
Prelude Therapeutics is an oncology company developing targeted therapies. Its value is determined almost entirely by the potential of its scientific developments and the success of its clinical trials. This chart demonstrates how biotech market valuations are based on future scientific breakthroughs rather than current tangible assets.
Debts of the company, segment and market as a whole
PRLD - Company debts Prelude Therapeutics
Prelude Therapeutics is a biopharmaceutical company focused on developing targeted cancer therapies. Its research requires significant and long-term funding. Raising debt capital allows the company to advance its innovative molecules through the complex and expensive stages of clinical development.
Market segment debts - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company specializing in oncology. Funding is key to advancing candidates through expensive trials. This chart shows whether the company follows the traditional biotech equity model or utilizes other financing instruments for its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Prelude Therapeutics
Prelude Therapeutics, an oncology company focused on lymphoma treatment, is in active clinical development. This chart illustrates its reliance on debt. For a biotech company, debt fuels research, but it carries enormous risk. Failure of a key drug could lead to the company's inability to service its obligations.
Market segment debt to market segment book capitalization - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company focused on developing targeted therapies for the treatment of oncology diseases, particularly lymphoma. This chart compares the debt it raised to fund cutting-edge research to the overall market capitalization of the entire sector. It illustrates the financial implications of developing precision cancer drugs.
Debt to book value of all companies in the market
Prelude Therapeutics is an oncology company in clinical development. Funding research is its primary focus. This chart shows how the company manages its capital. Its debt load, compared to the biotech sector, reflects how reliant it is on external financing to advance its drug candidates.
P/E of the company, segment and market as a whole
P/E - Prelude Therapeutics
This chart for Prelude Therapeutics, a clinical-stage oncology company, is an assessment of its scientific approach. Since there is no revenue from sales, the company's value is based on the potential of its drug candidates. The stock's performance reflects investors' faith that its research will lead to effective cancer treatments.
P/E of the market segment - Cancer lymphonodes
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Prelude Therapeutics. The entire sector is valued based on expectations for future drugs. For investors, this benchmark indicates the overall level of optimism. This provides a useful framework for assessing expectations for Prelude's developments.
P/E of the market as a whole
Prelude Therapeutics is a biotech company focused on developing small-molecule cancer therapies that target key signaling pathways in tumor cells. This chart illustrates the overall interest in oncology. It helps us understand how Prelude's scientific data and the progress of its clinical programs impact the company's valuation relative to many other players in this competitive field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Prelude Therapeutics
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule cancer drugs. This chart reflects analysts' confidence in the scientific potential of its candidates. It shows the future value they assign to the company, pending positive clinical trial data.
%20P%2FE%20Prelude%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Prelude-Therapeutics&v=1772625003737 "Chart of the company's future (projected) P/E Prelude Therapeutics")
Future (projected) P/E of the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting key drivers of cancer. This chart compares its future revenue expectations with the oncology sector. It demonstrates how the market views its scientific platform and the potential of its candidates for treating various cancer types.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-lymphonodes&v=1772625003761 "Future (projected) P/E graph of the market segment - Cancer lymphonodes")
Future (projected) P/E of the market as a whole
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on cancer treatments. This chart shows the company's overall risk appetite. Prelude's success depends on the results of clinical trials of its molecules. A positive market environment helps with funding, but cannot replace a scientific breakthrough, which is the primary driver.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772625003911 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Prelude Therapeutics
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that target key drivers of cancer. This chart shows the financial impact of cutting-edge oncology research. The results reflect investments in the development and clinical trials of next-generation anticancer drugs.
Profit of companies in the market segment - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule therapeutics targeting key drivers of cancer progression, particularly lymphatic cancer. This chart shows the total revenue in the oncology sector, reflecting the high level of investment and anticipation for new targeted therapies.
Overall market profit
Prelude Therapeutics is a biopharmaceutical company focused on developing targeted cancer therapies. Its prospects depend entirely on the success of its scientific platform. The need for cancer treatments is not subject to economic cycles. However, the overall market situation influences investor willingness to fund long-term research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Prelude Therapeutics
Prelude Therapeutics is a biotechnology company focused on developing targeted therapies for the treatment of cancer. Its approach is based on a deep understanding of the molecular mechanisms of the disease. This chart is a long-term model reflecting analysts' confidence in the company's scientific platform and its commercial potential.
%20profit%20of%20the%20company%20Prelude%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Prelude-Therapeutics&v=1772625004113 "Graph of future (projected) profit of the company Prelude Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule drugs for the treatment of cancer. This chart shows forecasts for the oncology segment of the biotech sector. Prelude's future profitability depends on the success of its drug candidates, which target key signaling pathways that control cancer cell growth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-lymphonodes&v=1772625004139 "Graph of future (predicted) profits of companies in a market segment - Cancer lymphonodes")
Future (predicted) profit of the market as a whole
Prelude Therapeutics is a biopharmaceutical company focused on oncology drugs. Its ability to fund expensive research and development is directly dependent on the overall investment climate. This graph, reflecting economic profit expectations, serves as an indicator of investor risk appetite, a key factor for the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772625004149 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Prelude Therapeutics
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of cancer. This chart demonstrates that the company's valuation is based on the potential of its scientific developments. It reflects investor expectations regarding clinical success and future revenue from its oncology portfolio.
P/S market segment - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule drugs that target key cancer drivers. Its approach is based on a deep understanding of cancer cell biology. This chart reflects the average biotech valuation, helping to understand how the market values Prelude's scientific platform and development potential.
P/S of the market as a whole
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its valuation is based on the future potential of its candidates. This graph of average market revenue estimates clearly illustrates how disconnected the valuations of pioneering biotech companies are from their current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Prelude Therapeutics
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of cancer. This chart reflects investor expectations for the future success of its extensive pipeline of candidates. The valuation is based on potential revenues from several drugs targeting various oncological diseases.
%20P%2FS%20Prelude%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Prelude-Therapeutics&v=1772625004380 "The graph of the company's future (projected) P/S Prelude Therapeutics")
Future (projected) P/S of the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in its scientific approach and the potential of its drug candidates.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-lymphonodes&v=1772625004454 "Future (projected) P/S market segment graph - Cancer lymphonodes")
Future (projected) P/S of the market as a whole
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting key drivers of cancer. This schedule reflects confidence in future growth, and Prelude is at the forefront of oncology. The success of its targeted therapies could offer new treatment options for difficult-to-treat cancers.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772625004542 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Prelude Therapeutics
Prelude Therapeutics is a clinical-stage biopharmaceutical company developing targeted cancer therapies. Its revenue, shown in this chart, is generated not from drug sales but primarily from payments under collaboration agreements with large pharmaceutical companies for the joint development of its candidates.
Sales of companies in the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of cancer. Their approach targets key signaling pathways in cancer cells. This graph reflects the dynamics of the oncology segment, where targeted therapies like Prelude's are one of the most promising areas.
Overall market sales
Prelude Therapeutics is a biotech company developing targeted drugs for the treatment of oncology. Its future depends on successful clinical trials. The growth in total revenue, reflected in this chart, improves the investment climate, making it easier for companies like Prelude to secure funding for expensive and time-consuming research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Prelude Therapeutics
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule therapeutics targeting key drivers of cancer progression. This chart reflects analyst expectations for the progress of its clinical programs and the potential of its targeted oncology therapy candidates.
%20sales%20of%20the%20company%20Prelude%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Prelude-Therapeutics&v=1772625004745 "Schedule of future (projected) sales of the company Prelude Therapeutics")
Future (projected) sales of companies in the market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that target key signaling pathways in cancer cells. This chart shows the oncology sector's outlook, allowing one to assess how Prelude's highly targeted approach fits into the overall cancer strategy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-lymphonodes&v=1772625004817 "Schedule of future (projected) sales of companies in the market segment - Cancer lymphonodes")
Future (projected) sales of the market as a whole
Prelude Therapeutics, an oncology company, sees this chart as an indicator of the overall health of the biotech sector. The optimistic economic outlook reflected here is fueling increased venture capital funding and M&A activity, creating a favorable environment for the development and commercialization of their developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772625004846 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Prelude Therapeutics
Prelude Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. This chart reflects the significant investments required for research and clinical trials. It is a measure of how the company manages its capital during the long journey to potential drug discovery.
Market segment marginality - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule drugs for the treatment of cancer. Their effectiveness is measured by the speed and cost of advancing candidates through clinical trials. The chart below provides an overview of the company's operating model compared to other oncology startups.
Market marginality as a whole
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on cancer treatments. This chart shows current market profitability, and Prelude is investing in drug discovery. Their financial history reflects their research expenditures, which could lead to the creation of valuable oncology assets.
Employees in the company, segment and market as a whole
Number of employees in the company Prelude Therapeutics
Prelude Therapeutics is an oncology company developing targeted therapies. Its team, visible in this graph, consists of scientists and drug development specialists. The size of its staff is an indicator of the intensity of its R&D activities and the breadth of its clinical pipeline.
Share of the company's employees Prelude Therapeutics within the market segment - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule drugs that target key cancer signaling pathways. This chart shows the percentage of oncology researchers Prelude attracts in its niche. This is a measure of its scientific potential and the scale of its research programs.
Number of employees in the market segment - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company developing targeted therapies for the treatment of oncology. Its staff consists of highly qualified scientists and researchers. The chart demonstrates the team's growth, which directly reflects progress in preclinical and early clinical trials of new drugs, which is key to the company's future.
Number of employees in the market as a whole
Prelude Therapeutics is a biopharmaceutical company focused on oncology. Its growth and hiring are driven by progress in drug development and investment. This chart shows the state of the economy, but for Prelude, successfully completing the next phase of clinical trials is far more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Prelude Therapeutics (PRLD)
Prelude Therapeutics is a clinical-stage oncology company. Its market capitalization reflects the market's faith in its scientific approach. This chart clearly demonstrates that the company's value is driven not by its headcount, but by the potential of its discoveries to fight cancer.
%20of%20the%20company%20Prelude%20Therapeutics%20(PRLD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Prelude-Therapeutics-PRLD&v=1772625005114 "Chart of market capitalization per employee (in thousands of dollars) of the company Prelude Therapeutics (PRLD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer lymphonodes
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule cancer drugs. The company's value lies in its scientific platform and the potential of its clinical candidates. This chart reflects the market value of each employee working on the development of next-generation oncology drugs.
%20by%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-lymphonodes&v=1772625005117 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer lymphonodes")
Market capitalization per employee (in thousands of dollars) for the overall market
Prelude Therapeutics is a biopharmaceutical company focused on developing small-molecule drugs for cancer treatment. Currently in clinical trials, its value is determined by the potential of its developments. The chart shows a high valuation per employee, typical for biotech, where intellectual capital is the primary asset.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772625005128 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Prelude Therapeutics (PRLD)
Prelude Therapeutics is a biopharmaceutical company specializing in targeted cancer therapy (small molecules). It's a pure R&D business. This graph will be negative, reflecting the amount of research investment per scientist. This is a bet that their scientific platform will create a breakthrough drug with enormous market potential.
%20Chart%20Prelude%20Therapeutics%20(PRLD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Prelude-Therapeutics-PRLD&v=1772625005159 "Company Profit Per Employee (in thousands of dollars) Chart Prelude Therapeutics (PRLD)")
Profit per employee (in thousands of dollars) in the market segment - Cancer lymphonodes
Prelude Therapeutics (PRLD) is a biopharmaceutical company specializing in the development of small-molecule cancer drugs targeting key signaling pathways. It is an R&D-intensive company. This chart shows how effectively the team of scientists utilizes capital to advance their platform and several candidates through the preclinical and early clinical stages.
%20in%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-lymphonodes&v=1772625005162 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer lymphonodes")
Profit per employee (in thousands of dollars) for the market as a whole
Prelude Therapeutics is a biotech company focused on oncology (specifically, lymphatic cancer). The company is in clinical trials. This graph illustrates a classic biotech trend: negative profit per employee. The company hires top scientists, and each represents a significant investment that will only pay off if clinical trials are successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772625005205 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Prelude Therapeutics (PRLD)
Prelude Therapeutics is a biopharmaceutical company developing targeted therapies for cancer. At the preclinical and clinical trial stages, this graph doesn't represent sales, but potential. Revenue per employee will likely be zero until a major partnership is struck or the first drug is approved.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Prelude-Therapeutics-PRLD&v=1772625005240 "Sales chart per company employee Prelude Therapeutics (PRLD)")
Sales per employee in the market segment - Cancer lymphonodes
Prelude Therapeutics is a biotech company focused on developing small-molecule drugs for cancer treatment. This chart shows the average revenue per employee in the sector. For an oncology R&D company, this is a benchmark. It demonstrates the industry-average productivity that Prelude will strive to achieve as it advances its candidates to market.
Sales per employee for the market as a whole
Prelude Therapeutics (PRLD) is a clinical-stage biotech company focused on developing small-molecule drugs (tablets) for the treatment of cancer. This is a science-intensive R&D company with a staff of scientists. This graph shows the current (zero) commercial return per employee pending clinical breakthroughs.
Short shares by company, segment and market as a whole
Shares shorted by company Prelude Therapeutics (PRLD)
Prelude Therapeutics is a clinical-stage oncology company working on kinase inhibitors. This is a very crowded area of cancer research. This chart shows the number of investors betting that Prelude's drugs will fail to stand out. They expect the candidates to show insufficient efficacy or to be too toxic in the clinic.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Prelude-Therapeutics-PRLD&v=1772625005277 "Short Shares Chart for the Company Prelude Therapeutics (PRLD)")
Shares shorted by market segment - Cancer lymphonodes
Prelude Therapeutics is a biotech company working on targeted cancer therapies. This indicator measures overall skepticism in the pharmaceutical industry. When it's high, it suggests that investors generally don't believe clinical trials will be successful or anticipate funding problems, which poses a risk to the entire industry in the early stages.
Shares shorted by the overall market
Prelude Therapeutics is a biotech company developing targeted cancer therapies. It's a highly competitive field. This chart reflects the overall market pessimism. When investors are worried, they look at Prelude's massive R&D spending and question whether the company will be able to attract new capital amid the funding drought.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Prelude Therapeutics (PRLD)
This chart shows the extreme volatility of Prelude Therapeutics. It's an early-stage oncology company whose stock is essentially a lottery ticket. Investors buy the stock, pushing the oscillator above 70, on the slightest positive preclinical data or at the start of human trials. The extremely high risk of failure in Phase 1 or 2 and the need for constant capital raising keep the indicator "oversold" most of the time.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Prelude-Therapeutics-PRLD&v=1772625005342 "RSI 14 indicator chart for the company's stock Prelude Therapeutics (PRLD)")
RSI 14 Market Segment - Cancer lymphonodes
Prelude (PRLD) is a biotech, a cancer hunter. Their specialty is small molecules targeting key cancer drivers (protein kinases). The "Cancer Lymphocytes" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is PRLD's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Prelude Therapeutics (PRLD) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRLD (Prelude Therapeutics)
Prelude (PRLD) is a clinical-stage oncology company developing small-molecule drugs targeting key cancer cell signaling pathways. This chart shows the average target price. It reflects analysts' speculative valuation of this scientific platform and its early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRLD-Prelude-Therapeutics&v=1772625005410 "A chart showing analyst consensus forecasts for the expected stock price. PRLD (Prelude Therapeutics)")
The difference between the consensus estimate and the actual stock price PRLD (Prelude Therapeutics)
Prelude Therapeutics (PRLD) is a clinical-stage oncology company developing targeted therapies (small molecules) for the treatment of cancer. This chart is a classic biotech barometer. It measures the vast gap between the current speculative price and the analyst consensus target. This gap reflects the enormous potential experts believe for the success of their R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRLD-Prelude-Therapeutics&v=1772625005425 "A chart showing the difference between the consensus forecast and the actual stock price. PRLD (Prelude Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer lymphonodes
Prelude Therapeutics is a clinical-stage biotech company developing small-molecule drugs (tablets) targeting key cancer drivers. This chart shows general expectations for the oncology sector. It reflects experts' confidence in the company's R&D pipeline.
Analysts' consensus forecast for the overall market share price
Prelude is a clinical-stage biotech company specializing in precision oncology. It's a risky R&D venture. This chart, which measures the market's overall risk appetite, is crucial. When optimism prevails, investors are willing to fund capital-intensive R&D projects. When pessimism rises, funding for companies like PRLD becomes scarce.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Prelude Therapeutics
Prelude Therapeutics is a biotech company focused on developing small molecules (pills) for cancer treatment. Their R&D engine targets specific proteins that control gene expression in cancer cells. This chart is a clear indicator of their R&D confidence. Its dynamics reflect the market's speculative assessment of their scientific platform and early clinical trial data.
AKIMA Market Segment Index - Cancer lymphonodes
Prelude Therapeutics (PRLD) is a biopharmaceutical company specializing in precision oncology. They develop small-molecule inhibitors for the treatment of cancer, particularly lymphomas and solid tumors. The chart shows the segment average. It helps investors assess how Prelude's risks and scientific potential compare to the average in the drug development sector.
The AKIM Index for the overall market
Prelude Therapeutics is a precision oncology company developing small molecules targeting key cancer drivers (protein degraders). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific platform compares to overall economic trends in oncology.
